Physician profile
Daniela Murphy
NPI 1700351285
$2,061.40
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,196 · 2022: $866.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.78 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.31 | 2021-2022 | |
| Insulet Corporation | $213.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $191.03 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.25 | 2021-2022 | |
| Lilly USA, LLC | $113.13 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $104.38 | 2021-2022 | |
| Pfizer INC. | $86.11 | 2021-2022 | |
| Glaxosmithkline, LLC. | $76.15 | 2022 | |
| Merck Sharp & Dohme LLC | $71.61 | 2021 | |
| Eisai INC. | $68.77 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $45.34 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.24 | 2022 | |
| Acerus Pharmaceuticals Corporation | $39.68 | 2021-2022 | |
| Astellas Pharma US INC | $39.25 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.06 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.60 | 2021 | |
| Novo Nordisk INC | $25.41 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $24.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.11 | 2022 | |
| Horizon Therapeutics Plc | $14.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2022 | |
| Cequr Corporation | $14.00 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.